Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines

Basic and Clinical Pharmacology and Toxicology

Volumn 102, Issue 4, 2008, Pages 399-407

  Takahata, Takenori ^a   Ookawa, Keizou ^b   Suto, Koji ^a   Tanaka, Masanori ^a   Yano, Hirohisa ^c   Nakashima, Osamu ^c   Kojiro, Masamichi ^c   Tamura, Yoshihiro ^a   Tateishi, Tomonori ^a   Sakata, Yuh ^d   Fukuda, Shinsaku ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Kuroishi City Hospital   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Misawa City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 3A4; ELACRIDAR; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MESSENGER RNA; NARINGENIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACRIDINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FLAVANONES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; NEOPLASM PROTEINS; RNA, MESSENGER; TETRAHYDROISOQUINOLINES; TRANSFECTION;

EID: 40849137843     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00199.x     Document Type: Article

References (40)

1. Kunimoto T, Nitta K, Tanaka T et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987 47 : 5944 7.
2. Rivory LP. Metabolism of CPT-11 impact on activity. Ann N Y Acad Sci 2000 922 : 205 15.
3. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP. Mechanism of action of camptothecin. Ann N Y Acad Sci 2000 922 : 1 10.
4. Shimada Y, Yoshino M, Wakui A et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993 11 : 909 13.
5. Boku N, Ohtsu A, Shimada Y et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999 17 : 319 23.
6. Guichard S, Terret C, Hennebelle I et al. CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues. Br J Cancer 1999 80 : 364 70.
7. Wu MH, Yan B, Humerickhouse R, Dolan ME. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res 2002 8 : 2696 700.
8. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000 60 : 1189 92.
9. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002 8 : 2605 11.
10. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991 51 : 4187 91.
11. Haaz M-C, Rivory L, Jantet S, Ratanasavanh D, Robert J. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol 1997 80 : 91 6.
12. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998 95 : 15665 70.
13. Maliepaard M, van Gastelen MA, de Jong LA et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999 59 : 4559 63.
14. Maliepaard M, van Gastelen MA, Tohgo A et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001 7 : 935 41.
15. Brangi M, Litman T, Ciotti M et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999 59 : 5938 46.
16. Rivory LP, Riou J-F, Haaz M-C et al. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996 56 : 3689 3694.
17. Dodds HM, Haaz M-C, Riou J-F, Robert J, Rivory LP. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 1998 286 : 578 83.
18. Haaz M-C, Rivory LP, Riché C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998 58 : 468 72.
19. Santos A, Zanetta S, Cresteil T et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000 6 : 2012 20.
20. Jansen WJM, Zwart B, Hulscher STM, Giaccone G, Pinedo HM, Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997 70 : 335 40.
21. van Ark-Otte J, Kedde MA, van der Vijgh WJF et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 1998 77 : 2171 6.
22. Imai Y, Tsukahara S, Asada S, Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 2004 64 : 4346 52.
23. Murakami T. Establishment and characterization of human hepatoma cell line (KIM-1). Acta Hepatol Jpn 1984 25 : 532 9.
24. Yano H, Kojiro M, Nakashima T. A new human hepatocellular carcinoma cell line (KYN-1) with a transformation to adenocarcinoma. In Vitro Cell Dev Biol 1986 22 : 637 46.
25. Yano H, Maruiwa M, Murakami T et al. A new human pleomorphic hepatocellular carcinoma cell line, KYN-2. Acta Pathol Jpn 1988 38 : 953 66.
26. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993 53 : 4595 602.
27. Ahmed SA, Gogal RM Jr., Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H] thymidine incorporation assay. J Immunol Methods 1994 170 : 211 24.
28. Mikami T, Ookawa K, Shimoyama T, Fukuda S, Saito H, Munakata A. Evaluation of CAR, Smad4, and KAI1 expression in colorectal tumors by an RT-PCR method. In : Hashimoto I, Shinkawa H, Suda T et al. (eds). Novel Findings of Gene Diagnosis, Regulation of Gene Expression, and Gene Therapy. Elsevier, Tokyo, Japan, 1999 153 8.
29. de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 1999 146 : 117 26.
30. Ho P-C, Saville DJ. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001 4 : 217 27.
31. Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, Sawada Y. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 2001 31 : 687 99.
32. Matsuoka H, Yano K, Seo Y, Saito T, Tomoda H, Takiguchi S. Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates. Anticancer Drugs 1995 6 : 413 8.
33. Fulco RA, Costa C, Germano MP et al. Hepatotoxicity of camptothecin derivatives in a primary culture system of rat hepatocytes. J Chemother 2000 12 : 345 51.
34. Chen Z-S, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K. ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 1999 55 : 921 8.
35. Fuhr U, Kummert AL. The fate of naringin in humans: A key to grapefruit juice-drug interactions? Clin Pharmacol Ther 1995 58 : 365 73.
36. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interaction. Br J Clin Pharmacol 1998 46 : 101 10.
37. Erlund I, Meririnne E, Alfthan G, Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange and grapefruit juice. J Nutr 2001 131 : 235 41.
38. Gornet J-M, Azoulay D, Duclos-Vallée J-C, Goldwasser F. Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11. Anticancer Drugs 2000 11 : 649 52.
39. van Riel JMGH, van Groeningen CJ, Kedde MA et al. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002 8 : 405 12.
40. O'Reilly EM, Stuart KE, Sanz-Altamira PM et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001 91 : 101 5.